These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 717257)

  • 1. Grandfathered drugs of 1938.
    Lewis BP; Castle RV
    Am Pharm; 1978 Dec; 18(13):36-9. PubMed ID: 717257
    [No Abstract]   [Full Text] [Related]  

  • 2. Counterfeit drugs.
    Rudolf PM; Bernstein IB
    N Engl J Med; 2004 Apr; 350(14):1384-6. PubMed ID: 15070787
    [No Abstract]   [Full Text] [Related]  

  • 3. A "relative efficacy" system for new drugs.
    Stolley PD; Goddard JL
    Ann Intern Med; 1970 Sep; 73(3):479-80. PubMed ID: 5455998
    [No Abstract]   [Full Text] [Related]  

  • 4. New classification of drugs.
    J Fla Med Assoc; 1972 Jan; 59(1):37. PubMed ID: 5058956
    [No Abstract]   [Full Text] [Related]  

  • 5. Today's dilemma--will drugs work?
    Dowling HF
    J Am Pharm Assoc; 1971 Jun; 11(6):331-3. PubMed ID: 5118797
    [No Abstract]   [Full Text] [Related]  

  • 6. Current trends in IND-NDA procedures.
    Brilhart KB
    Bull Parenter Drug Assoc; 1971; 25(3):132-9. PubMed ID: 5093249
    [No Abstract]   [Full Text] [Related]  

  • 7. Should the FDA impose relative efficacy judgments?
    Stetler CJ
    Tex Med; 1972 Nov; 68(11):48-52. PubMed ID: 4634627
    [No Abstract]   [Full Text] [Related]  

  • 8. FDA regulation of drugs, devices.
    Radzius JR
    AORN J; 1976 Aug; 24(2):254-5, 258-9, 262-3. PubMed ID: 1047997
    [No Abstract]   [Full Text] [Related]  

  • 9. Human and veterinary drugs: good manufacturing practices and proposed exemptions for certain OTC products.
    Fed Regist; 1978 Sep; 43(190 Pt 2):45013-89. PubMed ID: 10316700
    [No Abstract]   [Full Text] [Related]  

  • 10. Antibiotics standards versus standards for other drugs.
    Wright WW
    Am J Hosp Pharm; 1982 Jun; 39(6):1046-7. PubMed ID: 7102691
    [No Abstract]   [Full Text] [Related]  

  • 11. Isolator environments.
    Wagner CM
    PDA J Pharm Sci Technol; 1994; 48(4):175. PubMed ID: 7804813
    [No Abstract]   [Full Text] [Related]  

  • 12. Generic vs. brand name drugs--defining and enforcing standards.
    Lasagna LC
    Internist; 1979 May; 20(4):11, 13. PubMed ID: 10316827
    [No Abstract]   [Full Text] [Related]  

  • 13. Application of tolerances, standards, and methodology in the enforcement of the Food, Drug, and Cosmetic Act.
    Eiduson HP
    J Chem Inf Comput Sci; 1977 May; 17(2):102-5. PubMed ID: 853069
    [No Abstract]   [Full Text] [Related]  

  • 14. Generally Regarded As Safe.
    Novack GD
    Ocul Surf; 2017 Jan; 15(1):152-155. PubMed ID: 27871773
    [No Abstract]   [Full Text] [Related]  

  • 15. Curbing counterfeit drugs.
    FDA Consum; 2006; 40(5):11. PubMed ID: 17326307
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Report suggests steps to improve safety of drug supply.
    Traynor K
    Am J Health Syst Pharm; 2011 Sep; 68(17):1570, 1574. PubMed ID: 21856799
    [No Abstract]   [Full Text] [Related]  

  • 17. Regulating drugs for effectiveness and safety: a public health perspective.
    Zito JM; Socolar SJ; Eilers R; Crystal S; Lexchin J
    Med Care; 2007 Sep; 45(9):911. PubMed ID: 17712264
    [No Abstract]   [Full Text] [Related]  

  • 18. U.S. v. Barr Laboratories: a technical perspective.
    Madsen RE
    PDA J Pharm Sci Technol; 1994; 48(4):176-9. PubMed ID: 7804814
    [No Abstract]   [Full Text] [Related]  

  • 19. Toward more effective drug regulation.
    Schmidt AM
    FDA Consum; 1975 Dec-1976 Jan; 9(10):27-9. PubMed ID: 10316532
    [No Abstract]   [Full Text] [Related]  

  • 20. Response to the applicability of proposed large volume parenteral regulations to small volume parenteral drug products.
    Bull Parenter Drug Assoc; 1976; 30(6):265-79. PubMed ID: 1000103
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.